A-shares unusual movement | Innovative drugs collectively strengthen, San Sheng Guo Jian rises nearly 11%, dual positive factors of overseas expansion scale and approval numbers trigger a rally

The A-share market’s innovative drug concept stocks collectively surged. Among them, Hait Biomaterials rose nearly 12%, Sansheng Guojian rose nearly 11%, Lianhuan Pharmaceutical hit the 10% limit-up in a single day, and Shuanglu Pharmaceutical is approaching the limit-up. Selle Medical and NuoCheng JianHua both jumped more than 8%, Tonghua Dongbao rose more than 7%, and Baiyang Pharmaceutical, Kexing Pharmaceutical, Rongchang Bio, and Hongbo Pharmaceutical all rose more than 6%. In addition, Yinuosi and Zhaoyan New Pharma rose more than 5%. On the news front, in the first three months of this year, China’s innovative drug outbound licensing transaction total exceeded $60 billion, approaching half of the full-year figure for 2025. The latest statistics from the National Medical Products Administration show that, as of March 27, China has approved 10 innovative drugs for 2026, including 2 imported and 8 domestically developed. China’s innovative drugs have achieved a historic breakthrough, maintaining strong development momentum and potential.